PROGNOSTIC VALUE OF TRANSAMINASES AND BILIRUBIN LEVELS AT ADMISSION TO HOSPITAL ON DISEASE PROGRESSION AND MORTALITY IN PATIENTS WITH COVID-19 - AN OBSERVATIONAL RETROSPECTIVE STUDY.

SUPPLEMENTARY DATA

Supplementary Table S1: STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	1
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	*5*
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	6
		(*b*) Describe any methods used to examine subgroups and interactions	6
		(*c*) Explain how missing data were addressed	6
		(*d*) *Cohort study*—If applicable, explain how loss to follow-up was addressed	Not applicable

		(*e*) Describe any sensitivity analyses	6

Results			**Page**
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	7
		(b) Give reasons for non-participation at each stage	7
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	7
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) *Cohort study*—Summarise follow-up time (eg, average and total amount)	7
Outcome data	15*	*Cohort study*—Report numbers of outcome events or summary measures over time	
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
		(*b*) Report category boundaries when continuous variables were categorized	7
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7-8
Discussion			
Key results	18	Summarise key results with reference to study objectives	8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	9
Generalisability	21	Discuss the generalisability (external validity) of the study results	9-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

Supplementary Table S2: Demographic and clinical data of patients included and excluded from the study.

	Patients included in the study (CoviCamp database) N°(%): 1641 (79.9)	**Patients excluded from the study (CoviCamp database) N°(%): 413 (20.1)**	**p-value**
Males, N° (%)	1003 (61%)	264 (63%)	0.192
Age, years, mean (SD)	62.35(16.14)	61.77(15.51)	0.512
Charlson comorbidity index, mean (SD)	3 (2.43)	2.64(2.33)	0.006
N° (%) of patients with hypertension	779 (47.5%)	171 (41.4%)	0.799
N° (%) of patients with cardio-vascular disease	467 (28.5%)	107 (25.9%)	0.984
N° (%) of patients with diabetes	347 (21.1%)	73 (17.6%)	0.433
N° (%) of patients with chronic kidney disease	147 (9%)	31 (7.5%)	0.730
N° (%) of patients with chronic obstructive pulmonary disease	160 (9.8%)	52 (12.6%)	0.022
N° (%) of patients with chronic hepatopathy	63 (3.8%)	6 (1.4%)	0.053
N° (%) of patients with malignancy	112 (6.8%)	33(7.9%)	0.201